AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism

• Main Authors: Monika Rech (Author), Annika R. Kuhn (Author), Joost Lumens (Author), Paolo Carai (Author), Rick van Leeuwen (Author), Wouter Verhesen (Author), Robin Verjans (Author), Julie Lecomte (Author), Yilin Liu (Author), Joost J.F.P. Luiken (Author), Ronny Mohren (Author), Berta Cillero-Pastor (Author), Stephane Heymans (Author), Kèvin Knoops (Author), Marc van Bilsen (Author), Blanche Schroen (Author)
• Format: Book
• Published: Elsevier, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

MicroRNA-103/107 regulate systemic glucose metabolism and insulin sensitivity. For this reason, inhibitory strategies for these microRNAs are currently being tested in clinical trials. Given the high metabolic demands of the heart and the abundant cardiac expression of miR-103/107, we questioned whe...